Drug intelligence / Profile preview

FRP-003

Development stage: Unknown
Lead developer: Front Range Pharmaceuticals
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral, Sublingual

Overview

FRP-003 is an investigational, orally administered botanical drug candidate being developed by Front Range Pharmaceuticals (the pharmaceutical R&D division of Endourage) for the treatment of Long COVID, specifically targeting persistent fatigue and post-exertional malaise (PEM) in adults. FRP-003 is a standardized, full-spectrum hemp flower extract containing a specific blend of phytocannabinoids (including cannabidiol [CBD], cannabigerol [CBG], cannabidivarin [CBDV], cannabidiolic acid [CBDA], and cannabichromene [CBC]) and therapeutic terpenes (such as beta-caryophyllene, myrcene, limonene, linalool, and pinene). It is designed to support the endocannabinoid system and restore cellular homeostasis. In September 2026, the FDA cleared Front Range Pharmaceuticals' Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of FRP-003 in adults with Long COVID and persistent fatigue.

Brand names: Formula C
Other names: Formula C sublingual drops

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))AcetylcholinesteraseCNR1 (Cannabinoid receptor 1)GABAA (Gamma-aminobutyric acid receptor)TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on FRP-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FRP-003.